Synapse
⌘+K
Synapse
PulseExploreClubsResearchersJournals
Instagram
HomeClubsExplore
December 14, 2022Frontiers in PhysiologyOpen Access

Mitochondrial dysfunction in pulmonary arterial hypertension

View Full Paper
Ask AI
Bookmark
Share

Why the study?

PAH has high mortality and no curative drug, its pathogenesis remains not fully elucidated, and understanding mitochondrial metabolic mechanisms could help explore more comprehensive and specific treatment strategies.

Design

Review

Authors

WZWeiwei ZhangBLBo LiuYWYazhou Wang

Discussion

Loading...

Member takes

Overview

Highlights mitochondrial metabolism in PAH pathogenesis; leaves open whether targeting it improves outcomes.

Structured PICO

P
Population
Patients with pulmonary arterial hypertension (PAH)

Understanding mitochondrial metabolic mechanisms in PAH may lead to more comprehensive and specific treatment strategies.

Cite This Study

Zhang et al. (2022) studied this question.

synapsesocial.com/papers/6a8aa489176d2ac34cfbf093https://doi.org/10.3389/fphys.2022.1079989
View Full Paper
Ask AI
Bookmark
Share

Also Consider

Synapse has enriched 5 closely related papers on similar clinical questions. Consider them for comparative context:

  1. 1Mitochondrial Metabolism, Redox, and Calcium Homeostasis in Pulmonary Arterial Hypertension2022 · 40 citations
  2. 2Mitochondrial Dysfunction in Pulmonary Hypertension2023 · 27 citations
  3. 3Metabolism and Bioenergetics in the Right Ventricle and Pulmonary Vasculature in Pulmonary Hypertension2013 · 179 citations
  4. 4Multidimensional study on mitochondrial dysfunction in pulmonary hypertension2025
  5. 5Metabolic reprogramming: A novel metabolic model for pulmonary hypertension2022 · 16 citations